SERAPID absorbable colorless (4/0) DS-18 needle of 70 CM box of 24 sutures - Serag & Wiessner (3O153214) - Delynov

What is the SERAPID colorless absorbable suture (4/0)?

SERAPID from the brand Serag-Wiessner is a synthetic, absorbable, and colorless surgical suture material. Its structure is a braided multifilament type, which provides excellent handling. Manufactured from a glycolic acid homopolymer, this thread is covered with a coating composed of calcium stearate, polycaprolactone, or sucrose fatty acid esters to optimize intratissue passage. This 4/0 calibre device is supplied in a 70cm length. It is distinguished by faster absorption than the SERAFIT model, meeting the requirements of the European Pharmacopoeia for braided synthetic absorbable sutures.

What are the clinical indications in surgery?

In oral and implant surgery, SERAPID sutures from Serag-Wiessner are specifically indicated for soft tissue adaptation when short-term mechanical support is sufficient. They are ideal for procedures where rapid absorption is desired to limit bacterial plaque accumulation on the thread. This device is used for closing extraction sites, suturing periodontal flaps, or after implant placement, provided that healing does not require prolonged stability of the material. Its colorless nature ensures aesthetic discretion during procedures in the smile zone.

What are the technical characteristics of the DS-18 needle?

The DS-18 needle accompanying this 70cm suture has specific properties for dense tissues. The code 'DS' designates a 3/8 circle needle with a reverse cutting triangular tip. This geometry is designed to cross gingival or palatal tissues without risk of tearing, as the cutting edge is located on the outer curvature. The number 18 indicates a body length of 18 mm, providing a lever arm adapted to the restricted spaces of the oral cavity. Manufactured from high-quality surgical steel, it guarantees precise and constant penetration throughout the suturing procedure.

What are the contraindications for the use of this device?

The use of SERAPID is strictly contraindicated in clinical situations requiring long-term or permanent stability of the suture material. This product must not be used for performing ligatures, nor in specific contexts such as neurosurgery or cardiovascular surgery. Furthermore, its use is prohibited in patients with hypersensitivity or a known allergy to any of its components, notably glycolic acid or the coating agents (calcium stearate, polycaprolactone). It is imperative not to use this device if excessive tension on the wound edges is expected beyond the initial resistance period.

How does absorption occur and what are the precautions?

The absorption of SERAPID occurs by hydrolysis. This material is designed to be absorbed more rapidly than other references like SERAFIT, making it comparable to a Vicryl Rapide equivalent or Optime equivalent in terms of strength loss kinetics. Particular attention must be paid to patients with delayed healing or poor blood supply to the tissues, as this can lead to suture extrusion or delayed absorption. The practitioner must choose this 4/0 calibre taking into account the rapid degradation characteristics to ensure that mechanical support is sufficient during the critical phase of tissue reunion.

Who is the manufacturer and what standards are met?

This suture is manufactured by Serag-Wiessner GmbH & Co. KG, a recognized manufacturer based in Germany. The product benefits from a high level of regulatory safety, being classified as a Class III medical device. It bears the CE1014 marking, guaranteeing its compliance with current European requirements (MDR). The material complies with the European Pharmacopoeia monograph relating to sterile braided synthetic absorbable sutures. Each box contains 24 ready-to-use sutures, identified by the technical reference 3O153214, ensuring complete traceability for dental and oral surgery practices.

State of the art

Modern synthetic sutures - absorbable or non-absorbable - are central to wound healing in oral surgery. Recent advances focus on reducing post-operative infections.